Cosmo Pharmaceuticals N.V. (ETR: C43)
Germany
· Delayed Price · Currency is EUR 61.50
-2.50 (-3.91%)
Dec 19, 2024, 8:00 AM CET
Cosmo Pharmaceuticals Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 69.57 | -4.93 | 17.23 | 21.67 | -7.9 | -24.42 | Upgrade
|
| Depreciation & Amortization | 14.64 | 14.26 | 13.86 | 7.37 | 5.06 | 5.22 | Upgrade
|
| Other Amortization | - | - | - | - | 0.97 | 0.53 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.13 | 0.13 | - | - | -3.97 | 0.2 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 0 | - | 0.24 | 0.01 | Upgrade
|
| Loss (Gain) From Sale of Investments | -1.7 | -0.95 | -0.09 | 0.68 | 0.25 | 0.6 | Upgrade
|
| Loss (Gain) on Equity Investments | - | - | - | -17.75 | 4.94 | 5.06 | Upgrade
|
| Stock-Based Compensation | 3.47 | 3.83 | 2.08 | 1.46 | 9 | 10.08 | Upgrade
|
| Provision & Write-off of Bad Debts | 1.02 | 1.02 | - | - | - | - | Upgrade
|
| Other Operating Activities | 25.4 | 19.32 | 13.47 | 3.89 | 9.45 | -7.34 | Upgrade
|
| Change in Accounts Receivable | 5.19 | 5.19 | -14.16 | 3.29 | -7.92 | -3.71 | Upgrade
|
| Change in Inventory | -0.45 | -2.7 | 1.62 | -6.07 | 0.44 | -2.21 | Upgrade
|
| Change in Accounts Payable | 3.71 | 0.9 | -0.93 | 0.47 | 0.61 | -1.04 | Upgrade
|
| Change in Unearned Revenue | 1.49 | 1.4 | 0.51 | -0.94 | - | - | Upgrade
|
| Change in Income Taxes | -3.98 | -3.55 | -2.74 | -1.36 | -0.05 | - | Upgrade
|
| Change in Other Net Operating Assets | -1.16 | -0.3 | 2.39 | -0.46 | 1.78 | -2.07 | Upgrade
|
| Operating Cash Flow | 117.33 | 33.62 | 33.23 | 12.61 | 12.99 | -18.85 | Upgrade
|
| Operating Cash Flow Growth | 224.63% | 1.19% | 163.47% | -2.88% | - | - | Upgrade
|
| Capital Expenditures | -3.34 | -3.35 | -4.52 | -5.49 | -4.12 | -2.25 | Upgrade
|
| Cash Acquisitions | - | - | - | 23.34 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -16.12 | -11.96 | -2.79 | -2.99 | -3.97 | -15.07 | Upgrade
|
| Investment in Securities | 26.85 | 56.78 | -18.13 | 6.74 | 107.48 | -21.67 | Upgrade
|
| Other Investing Activities | 0.65 | 0.83 | 2.13 | 3.06 | 0.82 | -9.79 | Upgrade
|
| Investing Cash Flow | 8.05 | 42.3 | 1.69 | 24.86 | 75.45 | -48.69 | Upgrade
|
| Long-Term Debt Repaid | - | -176.03 | -0.92 | -2.62 | -1.79 | -1.75 | Upgrade
|
| Net Debt Issued (Repaid) | -176.03 | -176.03 | -0.92 | -2.62 | -1.79 | -1.75 | Upgrade
|
| Issuance of Common Stock | 2.45 | 0.69 | 0.27 | 0.76 | - | - | Upgrade
|
| Repurchase of Common Stock | -3.89 | -12.48 | -24.75 | -20.51 | -5.72 | -25.33 | Upgrade
|
| Common Dividends Paid | -4.22 | -16.89 | -15.61 | - | - | - | Upgrade
|
| Other Financing Activities | -7.94 | -6.56 | -5.13 | -4.88 | -4.38 | -7.38 | Upgrade
|
| Financing Cash Flow | -189.63 | -211.27 | -46.13 | -27.25 | -11.88 | -34.46 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.08 | -0.21 | -1.52 | 2.4 | -1 | 1.69 | Upgrade
|
| Net Cash Flow | -64.16 | -135.55 | -12.74 | 12.62 | 75.55 | -100.3 | Upgrade
|
| Free Cash Flow | 113.99 | 30.28 | 28.71 | 7.12 | 8.87 | -21.09 | Upgrade
|
| Free Cash Flow Growth | 251.82% | 5.45% | 303.00% | -19.64% | - | - | Upgrade
|
| Free Cash Flow Margin | 61.50% | 32.63% | 28.12% | 10.95% | 14.54% | -33.75% | Upgrade
|
| Free Cash Flow Per Share | 7.08 | 1.88 | 1.75 | 0.42 | 0.61 | -1.44 | Upgrade
|
| Cash Interest Paid | 2.23 | 4.38 | 4.38 | 4.38 | 4.38 | 4.38 | Upgrade
|
| Cash Income Tax Paid | 5.12 | 3.98 | 1.96 | 2.63 | -2.87 | 1.25 | Upgrade
|
| Levered Free Cash Flow | 72.86 | 16.18 | 11.7 | -10.47 | 1.41 | -24.54 | Upgrade
|
| Unlevered Free Cash Flow | 75.37 | 21.51 | 17.43 | -4.85 | 6.87 | -19.21 | Upgrade
|
| Change in Net Working Capital | -22.98 | -14.89 | 8.73 | 12.14 | 1.21 | 10.04 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.